Date:2/6/2012

ted timely or receive FDA approval; risks that the launch of BYDUREON will be delayed or unsuccessful; risks that we will not be successful in our efforts to expand the reach of our sales force or in our efforts to secure an exenatide development and commercial partner outside the U.S.; risks that our expense reductions will not be as large as we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or BYDUREON. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

(Financial information to follow)AMYLIN PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)Quarter ended
December 31, Twelve months ended
December 31, 2011201020112010Revenues:  Net product sales

$ 160,867$ 162,315$ 621,570$651,113  Revenues under collaborative agreements

4,06811,87529,10817,700Total revenues

164,935174,190650,678668,813Costs and expenses:  Cost of goods sold

12,31814,04248,37661,687  Selling, general and administrative

78,32362,548271,224276,880  Research and development

27,67137,510161,215183,083  Collaborative profit sharing

43,08363,071222,545257,127  Net costs to reacquire economic
interest in exenatide products

431,587-431,587-  Restructuring

1,7077,3287,19016,780Total costs and expenses

594,689184,4991,142,137795,557Operating loss

(429,754)(10,309)(491,459)(126,744)Interest and other expense, net

(31,717)(8,874)(51,940)(25,570)Net loss

$(461,471)$ (19,183)$(543,399)$(152,314)Net loss per share - basic and diluted

$ (3.15)$ (0.13)$ (3.73)$
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference